In the SUSTAIN 7 study patients in Ireland and internationally had more improvements in blood sugar and bodyweight levels with semaglutide compared with dulaglutide

Despite common mechanisms of actions, glucagon-like peptide-1 receptor agonists differ in structure, pharmacokinetic profile, and clinical effects. This head-to-head trial compared semaglutide with dulaglutide in patients with inadequately controlled type 2 diabetes

Read summary of results here
Read full article here